Drug interactions with lipid‐lowering drugs: Mechanisms and clinical relevance

@article{Neuvonen2006DrugIW,
  title={Drug interactions with lipid‐lowering drugs: Mechanisms and clinical relevance},
  author={Pertti J. Neuvonen and Mikko Niemi and Janne T. Backman},
  journal={Clinical Pharmacology \& Therapeutics},
  year={2006},
  volume={80}
}
Drug–drug interactions that interfere with statin metabolism
TLDR
The pharmacokinetic aspects of the drug–drug interaction with statins and genetic polymorphisms in CYPs, which are involved in the metabolism of statins, are discussed and the importance of establishing a system utilizing electronic medical information practically to avoid adverse drug reactions is highlighted.
Statin Muscle Toxicity and Genetic Risk Factors
TLDR
The principal relations known between statin myotoxicity and genetic risk factors are summarized in a review of statin-related muscle disorders.
Drug–Drug Interactions Between HMG-CoA Reductase Inhibitors (Statins) and Antiviral Protease Inhibitors
TLDR
Simvastatin and lovastatin have the highest potency for drug–drug interaction with potent CYP3A inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus, telaprevir or boceprevir, and therefore their coadministration is contraindicated.
Drug–drug interaction with statins
TLDR
The most important adverse effects associated with statins are myopathy and an asymptomatic increase in hepatic transaminases, both of which occur infrequently.
Comparative Hepatic and Intestinal Metabolism and Pharmacodynamics of Statins
TLDR
Compared with in vitro drug transporter and clinical data, the findings are applicable for use in comparative systems pharmacology modelling to predict the pharmacokinetics and pharmacological effects of statins at different dosages.
An updated review of interactions of statins with antibacterial and antifungal agents
TLDR
This work reviews and highlights major drug-drug interactions between statins and antibacterial and antifungal agents and suggests one possibility is to discontinue statins during daptomycin therapy, though no retrospective studies to date have shown a statistically significant elevation of adverse outcome risk.
Drug interactions with statins
TLDR
Possible adverse effects of statins can occur due to interactions in concomitant use of drugs that substantially inhibit or induce their methabolic pathway.
Clinically Important Drug Interactions Potentially Involving Mechanism-based Inhibition of Cytochrome P450 3A4 and the Role of Therapeutic Drug Monitoring
TLDR
To minimize drug-drug interactions involving mechanism-based CYP3A4 inhibition, it is necessary to choose safe drug combination regimens, adjust drug dosages appropriately, and conduct therapeutic drug monitoring for drugs with narrow therapeutic indices.
Effect of atorvastatin on CYP2C9 metabolic activity as measured by the formation rate of losartan metabolite in hypercholesterolaemic patients.
TLDR
Observations in a hypercholesterolaemic patient sample suggest that atorvastatin does not have a significant effect on enzymes encoded by the CYP2C9*1*1 and CYP1*2 genotypes when co-administered with a CYP 2C9 substrate, losartan.
Effect of Gemfibrozil and Fenofibrate on the Pharmacokinetics of Atorvastatin
TLDR
Gemfibrozil increases systemic exposure to various different statins, whereas similar effects are not observed with fenofibrate, suggesting it may be a more appropriate choice for coadministration with statins.
...
...

References

SHOWING 1-10 OF 173 REFERENCES
Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update
  • M. Schachter
  • Biology, Chemistry
    Fundamental & clinical pharmacology
  • 2005
TLDR
Clinical studies have demonstrated rosuvastatin to be the most effective for reducing low‐density lipoprotein cholesterol, followed by atorvastsatin, simvastasin and pravastatin, and the bioavailability of the statins differs greatly, from 5% for lovastatin and simvASTatin to 60% or greater for cerivastatinand pitavastatin.
HMG-CoA Reductase Inhibitors (Statins) Characterized as Direct Inhibitors of P-Glycoprotein
TLDR
This study shows directly, as well as quantifies, the inhibition of P-gp-mediated transport of a fluorescent marker substrate, which indicates that the clinical interactions of statins with other drugs may be due, in part or all, to inhibition ofP-gp transport.
Clinical Pharmacokinetics of Fluvastatin
TLDR
Fluvastatin is relatively hydrophilic, compared with the semisynthetic HMG-CoA reductase inhibitors, and, therefore, it is extensively absorbed from the gastrointestinal tract, and does not appear to have a significant effect on other CYP isoenzymes or P-glycoprotein-mediated transport in vivo.
Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors
TLDR
Rhabdomyolysis has occurred following the coadministration of cyclosporin, a potent CYP3A4 and P-glycoprotein inhibitor, and lovastatin, and the patient should be monitored for signs and symptoms of myopathy and the statin should be discontinued if necessary.
Effects of Acid and Lactone Forms of Eight HMG-CoA Reductase Inhibitors on CYP-Mediated Metabolism and MDR1-Mediated Transport
TLDR
The difference between the acid and lactone forms in terms of drug interaction was showed, and a significant correlation was found between the lipophilicity and inhibitory effects on CYP2C8-mediated paclitaxel 6α-hydroxylation.
In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors
TLDR
Fluvastatin selectively inhibits a major drug metabolising enzyme (CYP2C9), the (+)-isomer (pharmacologically more active) showing 4–5 fold higher affinity.
Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors
TLDR
It is demonstrated that CYP-mediated metabolism of lactones is also a common metabolic pathway for statins and that the CYP3A4- mediated metabolism of the lactone forms clearly will need to be taken into account in assessing mechanistic aspects of drug–drug interaction involving statins.
Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics.
TLDR
Multiple transporters mediate the overall hepatic uptake of rosuvastatin, and NTCP may be a heretofore unrecognized transporter important to the disposition of roviastatin and possibly other drugs/statins in clinical use.
Effects of fibrates on metabolism of statins in human hepatocytes.
TLDR
The results suggest that there is a potential difference between fibrates in their ability to affect the pharmacokinetics of statins, and among statins in their susceptibility to metabolic interactions with GFZ in humans.
...
...